Abstract:
Compositions and methods for identifying nucleotide fragments that contain an open reading frame are provided. Compositions comprise a nucleotide sequence that encodes, in each of the three possible reading frames, an ATG start codon and a histidine tag, and vectors comprising such a nucleotide sequence. The vectors may be provided with cloning sites for insertion of nucleotide sequences of interest 5′ or 3′ to the 3-frame His-tag DNA sequence. Vectors also are provided with cloning sites for inserting nucleotide sequences of interest 3′ of the ATG start codon and 5′ of the 3-frame His-tag DNA sequence.
Abstract:
A method to improve silicon oxynitride when used as an etching stop for silicon oxide plasma etching, by nitridizing with a nitrogen plasma, in the fabrication of an integrated circuit is achieved. The method is applied to forming etch stopping silicon oxynitride spacers for MOS transistors and for forming etch stopping silicon oxynitride for dual damascene interconnects. A semiconductor substrate is provided wherein devices and features have been formed in and on the semiconductor substrate. A silicon oxynitride layer is deposited overlying the semiconductor substrate. The silicon oxynitride layer is nitridized. An interlevel dielectric oxide layer is deposited overlying surface of the silicon oxynitride layer. The interlevel dielectric oxide layer is etched through to the silicon oxynitride layer where defined by photolithography and wherein the silicon oxynitride layer acts as an etching stop. The exposed silicon oxynitride layer is etched through to expose the top surface of the underlying semiconductor substrate. The integrated circuit is completed.
Abstract:
Lightweight concrete products, useful for example in blocks, wall panels, floor and roof slabs, in which zeolite is a major component, its content in the cementing material of the products exceeding 50 wt. %. Depending on application, zeolite may be non-treated or calcined at a temperature enabling the surface activation of the zeolite and resulting high surface energy. Zeolite thus treated will work as both pozzolanic material and bubble-generating agent. Strengthening agents are used to improve compressive strength of the products. Also, a binding material, useful for hazardous waste stabilization, comprising zeolite as a major component, is proposed.
Abstract:
A method, apparatus, system, and article of manufacture provide object descriptors for objects in point cloud data for an urban environment by segmenting the point cloud data. Point cloud data for an urban environment is obtained using a ground-based laser scanner. Terrain points are filtered out from the point cloud data using ground filtering. The point cloud data is then segmented into two or more blocks. Objects that lie on neighboring adjacent blocks are combined. Object descriptors for the combined objects are then provided (e.g., to the user or a program used by the user).
Abstract:
The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.
Abstract:
A work piece includes a copper bump having a top surface and sidewalls. A protection layer is formed on the sidewalls, and not on the top surface, of the copper bump. The protection layer includes a compound of copper and a polymer, and is a dielectric layer.
Abstract:
An approach is provided for selecting a network server. An apparatus comprising at least one processor, and at least one memory including computer program code, the at least one memory and the computer program code configured to, with the at least one processor, cause, at least in part, the apparatus to load from one or more network servers configuration information of one or more network servers used by a service provider network. The apparatus is also caused to select a network server in the service provider network based at least in part on at least one of network server latency and the network server load. The apparatus is further caused to set the network server as default network server used for at least one of current and future session on one or more user equipment.
Abstract:
The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.
Abstract:
The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.
Abstract:
The present invention provides an anti-tumor or anti-angiogenesis medicament, the combination or kit containing the medicament, and the method for producing the same. The anti-tumor or anti-angiogenesis medicament contains a conjugate comprising a modifying agent and the angiostatin or its fragments, wherein the conjugate exhibits prolonged in vivo half-life as compared to an unmodified angiostatin or its fragments. The modifying agent is selected from the group consisting of macromolecular polymers, protein molecules or fragments thereof, peptides, small molecules, or chemical substances of any other forms.